Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Wireless oxygen sensor for newborns put to the test

NCT ID NCT07813091

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are testing the oxygen-reading part of a new wireless monitoring system called NeWTS. They want to see whether it measures blood oxygen as accurately as a standard wired clinical monitor and a gold-standard blood gas analyser. The study enrolls 24 healthy adults aged 18 to 55, not newborns, as an early step before the device is considered for use in neonatal intensive care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a wireless oxygen monitoring device called the Neonatal Wireless Transmission System
What this could lead to
If it works, the device could give newborns in intensive care a wireless way to have their blood oxygen tracked, without the tangle of wires.
What could go wrong
This is an early device test in healthy adults, not babies. Readings that look accurate in adults may not hold up in newborns, and the device may not match standard blood tests closely enough to be trusted in the NICU.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be aged 18-55 years * Willing and have capacity to provide written informed consent * Healthy adult volunteers classified as ASA 1 * Non-smoker (this does not exclude vaping) * Willing and able to comply with study procedures and duration Exclusion Criteria: * History of Bleomycin treatment at any time * Smokers or individuals exposed to high levels of carbon monoxide * Compromised circulation, injury, or physical malfunction of the sensor sites which would limit the ability to test sites needed for the study * Morbidly obese (defined as BMI \>39.5) or significantly underweight (BMI \<18) * Pregnancy * Participants who can conceive a pregnancy or carry a child (including women, trans men and non-binary people) will be required to demonstrate a negative pregnancy test * Unwillingness or inability to remove coloured nail polish or nail attachments from test digits (relevant for reference pulse oximeter) or to have medical monitoring attached * Known health conditions or medications disclosed on Health Assessment Form which mean that participant is not healthy * Allergy to lidocaine * Known allergy to adhesives used in medical dressings or tapes or materials used to adhere NeWTS components. * Enrolment in any other clinical investigation/trial that is deemed would compromise the validity of the data or safety of the patient (at the discretion of the local PI) * Sunburn/spray tan or other pigments on hands

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Device performance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Research Facility

    Birmingham, England, B15 2GW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.